Dominik J. Ose, Emmanuel Adediran, Bayarmaa Mark, Krista Ocier, William A. Dunson JR, Cindy Turner, Belinda Taylor, Kim Svoboda, Andrew R. Post, Jennifer Leiser, Howard Colman, Cornelia M. Ulrich, Mia Hashibe
{"title":"癌症患者糖尿病与常规收集的患者报告结果之间的关系。一项真实世界队列研究。","authors":"Dominik J. Ose, Emmanuel Adediran, Bayarmaa Mark, Krista Ocier, William A. Dunson JR, Cindy Turner, Belinda Taylor, Kim Svoboda, Andrew R. Post, Jennifer Leiser, Howard Colman, Cornelia M. Ulrich, Mia Hashibe","doi":"10.1002/cam4.70246","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Current studies have indicated that diabetes mellitus (DM) is highly prevalent in patients with cancer, but there is little research on consequences on the well-being of patients during cancer treatment. This analysis evaluates the relationship between DM and patient-reported outcomes (PRO) in patients with cancer, using a large and well-characterized cohort.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study utilized the Total Cancer Care protocol at the University of Utah Huntsman Cancer Institute. For this analysis, we integrated data from electronic health records, the Huntsman Cancer Registry, and routinely collected PRO questionnaires. We assessed the association between DM in patients with cancer and PRO scores for anxiety, depression, fatigue, pain interference, and physical function using multiple linear regression and t-tests.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The final cohort comprised 3512 patients with cancer, with a mean age of 57.8 years at cancer diagnosis. Of all patients, 49.1% (<i>n</i> = 1724) were female, with 82.0% (<i>n</i> = 2879) patients reporting PROs at least at one time point. Compared with patients who responded, nonresponders were more often female (<i>p</i> = 0.0035), less frequently non-Hispanic White (<i>p</i> = 0.0058), and had a higher BMI (<i>p</i> = 0.0759). Patients with cancer and diabetes had worse PRO scores for anxiety (<i>p</i> = 0.0003), depression (<i>p</i> < 0.0001), fatigue (<i>p</i> < 0.0001), pain interference (<i>p</i> < 0.0001), and physical function (<i>p</i> < 0.0001) compared to patients with cancer without diabetes. Significant associations between diabetes and PRO scores were observed for anxiety (<i>β</i> ± SE: 1.27 ± 0.48; <i>p</i> = 0.0076), depression (<i>β</i> ± SE: 1.46 ± 0.45; <i>p</i> = 0.0011), fatigue (<i>β</i> ± SE: 2.11 ± 0.52; <i>p</i> < 0.0001), pain interference (<i>β</i> ± SE: 1.42 ± 0.50; <i>p</i> = 0.0046), and physical function (<i>β</i> ± SE: −2.74 ± 0.48; <i>p</i> < 0.0001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The results of this study suggest that patients with cancer and diabetes may be at greater risk for anxiety, depression, fatigue, higher pain interference, and reduced physical function. Strengthening diabetes management is imperative to address the negative impact of diabetes on PROs. In particular, this may be true for patients with skin, breast, prostate, and kidney cancer.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 20","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500209/pdf/","citationCount":"0","resultStr":"{\"title\":\"The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study\",\"authors\":\"Dominik J. Ose, Emmanuel Adediran, Bayarmaa Mark, Krista Ocier, William A. Dunson JR, Cindy Turner, Belinda Taylor, Kim Svoboda, Andrew R. Post, Jennifer Leiser, Howard Colman, Cornelia M. Ulrich, Mia Hashibe\",\"doi\":\"10.1002/cam4.70246\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Current studies have indicated that diabetes mellitus (DM) is highly prevalent in patients with cancer, but there is little research on consequences on the well-being of patients during cancer treatment. This analysis evaluates the relationship between DM and patient-reported outcomes (PRO) in patients with cancer, using a large and well-characterized cohort.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This study utilized the Total Cancer Care protocol at the University of Utah Huntsman Cancer Institute. For this analysis, we integrated data from electronic health records, the Huntsman Cancer Registry, and routinely collected PRO questionnaires. We assessed the association between DM in patients with cancer and PRO scores for anxiety, depression, fatigue, pain interference, and physical function using multiple linear regression and t-tests.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The final cohort comprised 3512 patients with cancer, with a mean age of 57.8 years at cancer diagnosis. Of all patients, 49.1% (<i>n</i> = 1724) were female, with 82.0% (<i>n</i> = 2879) patients reporting PROs at least at one time point. Compared with patients who responded, nonresponders were more often female (<i>p</i> = 0.0035), less frequently non-Hispanic White (<i>p</i> = 0.0058), and had a higher BMI (<i>p</i> = 0.0759). Patients with cancer and diabetes had worse PRO scores for anxiety (<i>p</i> = 0.0003), depression (<i>p</i> < 0.0001), fatigue (<i>p</i> < 0.0001), pain interference (<i>p</i> < 0.0001), and physical function (<i>p</i> < 0.0001) compared to patients with cancer without diabetes. Significant associations between diabetes and PRO scores were observed for anxiety (<i>β</i> ± SE: 1.27 ± 0.48; <i>p</i> = 0.0076), depression (<i>β</i> ± SE: 1.46 ± 0.45; <i>p</i> = 0.0011), fatigue (<i>β</i> ± SE: 2.11 ± 0.52; <i>p</i> < 0.0001), pain interference (<i>β</i> ± SE: 1.42 ± 0.50; <i>p</i> = 0.0046), and physical function (<i>β</i> ± SE: −2.74 ± 0.48; <i>p</i> < 0.0001).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The results of this study suggest that patients with cancer and diabetes may be at greater risk for anxiety, depression, fatigue, higher pain interference, and reduced physical function. Strengthening diabetes management is imperative to address the negative impact of diabetes on PROs. In particular, this may be true for patients with skin, breast, prostate, and kidney cancer.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"13 20\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500209/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70246\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70246","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study
Objective
Current studies have indicated that diabetes mellitus (DM) is highly prevalent in patients with cancer, but there is little research on consequences on the well-being of patients during cancer treatment. This analysis evaluates the relationship between DM and patient-reported outcomes (PRO) in patients with cancer, using a large and well-characterized cohort.
Methods
This study utilized the Total Cancer Care protocol at the University of Utah Huntsman Cancer Institute. For this analysis, we integrated data from electronic health records, the Huntsman Cancer Registry, and routinely collected PRO questionnaires. We assessed the association between DM in patients with cancer and PRO scores for anxiety, depression, fatigue, pain interference, and physical function using multiple linear regression and t-tests.
Results
The final cohort comprised 3512 patients with cancer, with a mean age of 57.8 years at cancer diagnosis. Of all patients, 49.1% (n = 1724) were female, with 82.0% (n = 2879) patients reporting PROs at least at one time point. Compared with patients who responded, nonresponders were more often female (p = 0.0035), less frequently non-Hispanic White (p = 0.0058), and had a higher BMI (p = 0.0759). Patients with cancer and diabetes had worse PRO scores for anxiety (p = 0.0003), depression (p < 0.0001), fatigue (p < 0.0001), pain interference (p < 0.0001), and physical function (p < 0.0001) compared to patients with cancer without diabetes. Significant associations between diabetes and PRO scores were observed for anxiety (β ± SE: 1.27 ± 0.48; p = 0.0076), depression (β ± SE: 1.46 ± 0.45; p = 0.0011), fatigue (β ± SE: 2.11 ± 0.52; p < 0.0001), pain interference (β ± SE: 1.42 ± 0.50; p = 0.0046), and physical function (β ± SE: −2.74 ± 0.48; p < 0.0001).
Conclusions
The results of this study suggest that patients with cancer and diabetes may be at greater risk for anxiety, depression, fatigue, higher pain interference, and reduced physical function. Strengthening diabetes management is imperative to address the negative impact of diabetes on PROs. In particular, this may be true for patients with skin, breast, prostate, and kidney cancer.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
